Opko Health Inc. (OPK) Rating Lowered to Neutral at J P Morgan Chase & Co
Opko Health Inc. (AMEX:OPK) was downgraded by investment analysts at J P Morgan Chase & Co from an “overweight” rating to a “neutral” rating in a research note issued to investors on Thursday, StockTargetPrices.com reports.
Separately, Jefferies Group LLC restated a “hold” rating and set a $8.00 price objective on shares of Opko Health in a research report on Tuesday, June 13th.
Shares of Opko Health (AMEX:OPK) traded down 6.88% during trading on Thursday, hitting $6.03. The stock had a trading volume of 20,917,452 shares. Opko Health has a 12-month low of $5.85 and a 12-month high of $12.15. The stock’s 50-day moving average is $6.22 and its 200-day moving average is $6.90. The stock’s market capitalization is $3.37 billion.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.